Therapeutic Area
Oncology CDMOs
Compare CDMOs with oncology manufacturing experience for cytotoxic compounds, antibody-drug conjugates (ADCs), and targeted therapies. Filter by containment level, modality, and scale.
386 companies listed
About Oncology Drug Manufacturing
Oncology is the largest therapeutic area by R&D spend, with over 2,000 drugs in clinical development globally. Manufacturing oncology products demands specialized capabilities: cytotoxic handling for traditional chemotherapy agents, high-potency containment for targeted small molecules, and bioconjugation expertise for the growing ADC (antibody-drug conjugate) pipeline.
Containment is non-negotiable. Most oncology APIs have occupational exposure limits (OELs) below 10 micrograms per cubic meter, requiring OEB4 or OEB5 engineering controls. This means dedicated facilities with isolators, continuous liner systems, split-butterfly valves, and validated cleaning procedures to prevent cross-contamination. Not every CDMO claiming "potent compound handling" can actually operate at OEB5 levels.
ADCs represent a unique manufacturing challenge. They combine biologics (monoclonal antibody production), small molecule chemistry (cytotoxic payload synthesis and linker chemistry), and bioconjugation (attaching payload to antibody). Few CDMOs can handle all three steps in-house. Most ADC sponsors work with 2-3 specialized CDMOs and manage the tech transfer between them.
Companies (386)
Fisher BioServices (Thermo Fisher)
Netherlands
Fisher BioServices is part of Thermo Fisher Scientific's Patheon pharma services division, one of the world's largest CDMOs offering end-to-end 360-degree CDMO and CRO solutions. The Patheon platform covers drug substance and drug product manufacturing for small molecules, large molecules, and advanced therapies, along with clinical supply and commercialization services.
Biologics Drug SubstanceBiologics Drug ProductBiologics Manufacturing
Forge Biologics (Ajinomoto Group)
United States
Forge Biologics, acquired by Ajinomoto Group in 2023 for $554-620 million, is a gene therapy CDMO specializing in high-purity adeno-associated virus (AAV) vector and plasmid manufacturing. The company operates a 200,000 sq ft Hearth facility in Columbus, Ohio with 20 cGMP suites and 20,000L bioreactor capacity, providing end-to-end services from preclinical process development through commercial manufacturing.
Frequently Asked Questions
What special capabilities do oncology CDMOs need?+
Oncology CDMOs need high-potency compound handling (OEB4/OEB5 containment with isolators and engineering controls), dedicated or segregated manufacturing suites to prevent cross-contamination, specialized waste handling for cytotoxic materials, worker safety programs including medical surveillance, and analytical methods validated for potent compound detection at very low levels. For ADCs, they additionally need bioconjugation suites and experience with linker-payload chemistry.
Why is containment critical for cancer drug manufacturing?+
Most oncology drugs are designed to kill rapidly dividing cells -- a property that makes them effective against tumors but hazardous to workers. Occupational exposure to cytotoxic compounds can cause skin irritation, reproductive harm, and potentially cancer. OEB4 and OEB5 containment (exposure limits below 1 microgram/m3) uses engineering controls -- isolators, airlocks, continuous liners, and HEPA-filtered exhaust -- to protect workers while maintaining product quality.
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
